Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Development of Broadly Protective Filovirus Vaccines

Project description

Vaccines against Filoviruses

Filoviruses, including Ebola virus and Marburg virus, are highly infectious pathogens that can cause severe and often fatal hemorrhagic fever in humans. The development of vaccines against filoviruses has been a critical focus of research due to the potential for large-scale outbreaks and the lack of effective treatments. The EU-funded FILOVAX project aims to develop preventive vaccination tools, particularly for high-risk groups like healthcare workers. The idea is to generate multivalent vaccines that cover different Filoviruses and establish a vaccine library for all known strains. Clinical data from phase I and phase II trials will pave the way for vaccine licensing and prompt implementation to effectively manage epidemic and pandemic outbreaks.

Objective

The overall objective of the proposed broadly protective Filovirus vaccine project is to leverage co-funding from the European Commission to support the development of vaccines that will protect against a range of Filoviruses. Within this viral family, Ebolaviruses and Marburgvirus are endemic to West and Central Africa and cause frequent unpredictable outbreaks of varying size and duration. These outbreaks have significant health and societal impacts on populations in the endemic regions. In order to better prepare for future outbreaks of Zaire ebolavirus and other Filoviruses, it is necessary to develop tools to preventively vaccinate at-risk populations, such as health-care workers, in endemic regions. The impact of such preventive vaccinations would be greatest if the vaccines protected against a broad range of Filoviruses that emerge in those regions.

This project therefore aims to support the development of broadly protective Filovirus vaccines for preventive use. This will be achieved through two focused areas of work: (i) advancing the development of multivalent vaccines composed of single valencies covering different Filoviruses, taking a monovalent-first approach whereby individual vaccine candidates are progressed as critical building blocks and intermediate steps toward multivalent formulations, and (ii) the development of a vaccine library comprised of all known Filoviruses. The output of the work under this project will be multivalent vaccines with phase II clinical data to support a pathway to licensure, and individual exemplar candidates from a vaccine library with phase I clinical data. This co-funded grant application seeks to leverage €35m from Horizon Europe, which will be supplemented with €15m from CEPI making a total pool of €50m. Awards to support the project aims will be administered and managed by the CEPI secretariat, and the total project duration will be 66 months. This project builds on the existing partnership between the CEPI and the European Union which seeks to accelerate vaccine development for priority pathogens causing epidemic and pandemic threats collaboratively and effectively.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-COFUND - HORIZON Programme Cofund Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2023-CEPI-11-IBA

See all projects funded under this call

Coordinator

COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS
Net EU contribution
€ 35 000 000,00
Address
SKOYEN ATRIUM ASKEKROKEN 11
0277 Oslo
Norway
Region
Norge Oslo og Viken Oslo
Activity type
Research Organisations
Links
Total cost
€ 50 000 000,00